GSK1838705A是高效可逆的多靶点抑制剂，对ALK抑制活性最强（IC₅₀=0.5nM），对胰岛素受体（IC₅₀=1.6nM）和IGF-IR（IC₅₀=2.0nM）活性接近，且对其他蛋白激酶几乎无作用，选择性极高。

[1] Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K, Kruger RG, Gontarek RR, Maksimchuk KR, Suravajjala S, Lapierre RR, Shotwell JB, Wilson JW, Chamberlain SD, Rabindran SK, Kumar R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. doi: 10.1158/1535-7163.MCT-09-0423. PMID: 19825801.